This hypothesis is supported by preclinical studies in which PI3K inhibitors overcame PTEN loss-induced trastuzumab resistance and slowed the growth of HER2+ breast cancer cells in vitro and in vivo[51,52]. The gene discussed is ERBB2; the disease is breast carcinoma.